{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-297614","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2023-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.337267+00:00","generated_at":"2026-06-07T11:22:56.085752+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Mirum's LIVMARLI fails Phase 2b EMBARK trial in biliary atresia; primary endpoint not met","bullets":["Phase 2b EMBARK trial of LIVMARLI (maralixibat) in biliary atresia did not meet primary or key secondary endpoints.","LIVMARLI was generally well-tolerated with no new safety findings.","Topline results announced on December 18, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-297614","json":"https://secwatch.observer/filing/0001193125-23-297614.json","markdown":"https://secwatch.observer/filing/0001193125-23-297614.md","text":"https://secwatch.observer/filing/0001193125-23-297614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523297614/0001193125-23-297614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523297614/d784519d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T11:22:56.085752+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}